Research demonstrates novel spleen-targeting nanocarriers for immune modulation in colitis, suggesting new therapeutic pathways.
Vesicle-Fused Lipid Nanoparticles In their Research Article (10.1002/adfm.202516976), by fusing human red blood cell membranes with immunomodulatory drug-encapsulated lipid nanoparticles, Han Young Kim and co-workers present biomimetic hybrid nanocarriers that exploit erythrophagocytosis-driven red blood cell clearance pathways for spleen targeting. This modular fusion approach enables customizable nanocarrier design and controlled immune modulation within secondary lymphoid organs.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: